Myasthénie auto-immune oculaire : le traitement par prednisone un essai randomisé contrôlé

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar de l’utilisateur

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 4692
Inscription : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 8.1 Firefox
Genre :
Résidence : France
Zodiaque : Lion
Âge : 60
Contact :

Myasthénie auto-immune oculaire : le traitement par prednisone un essai randomisé contrôlé

Message par Pboulanger » 27 avr. 2016 10:44

:hi:

Lu sur http://www.ncbi.nlm.nih.gov/pubmed/2617 ... t=Abstract
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Image
Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.
Benatar M1, Mcdermott MP1, Sanders DB1, Wolfe GI1, Barohn RJ1, Nowak RJ1, Hehir M1, Juel V1, Katzberg H1, Tawil R1; Muscle Study Group (MSG).
Muscle Nerve. 2016 Mar;53(3):363-9. doi: 10.1002/mus.24769. Epub 2016 Jan 27.


Abstract

  • INTRODUCTION:
    In this study we evaluated the safety, tolerability, and efficacy of prednisone in patients with ocular myasthenia gravis (OMG) concurrently treated with pyridostigmine.
  • METHODS:
    This investigation was a randomized, double-blind, placebo-controlled trial. Participants whose symptoms failed to remit on pyridostigmine were randomized to receive placebo or prednisone, initiated at 10 mg every other day, and titrated to a maximum of 40 mg/day over 16 weeks. The primary outcome measure was treatment failure.
  • RESULTS:
    Fewer subjects were randomized than the 88 planned. Of the 11 randomized, 9 completed 16 weeks of double-blind therapy. Treatment failure incidence was 100% (95% CI 48%-100%) in the placebo group (n = 5) vs. 17% (95% CI 0%-64%) in the prednisone group, P = 0.02 (n = 6). Median time to sustained minimal manifestation status (MMS) was 14 weeks, requiring an average prednisone dose of 15 mg/day. Adverse events were infrequent and generally mild in both groups.
  • CONCLUSIONS:
    A strategy of low-dose prednisone with gradual escalation appears to be safe, well-tolerated, and effective in treating OMG
Muscle Nerve 53: 363-369, 2016.
© 2015 Wiley Periodicals, Inc.
Amicalement,
Image

Répondre

Revenir vers « Informations »

Qui est en ligne ?

Utilisateurs parcourant ce forum : Aucun utilisateur inscrit et 0 invité